prikaz prve stranice dokumenta Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
  Download
PDF 571.52 KB
Scientific paper - Original scientific paper
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
Frontiers in Immunology, 14 (2023); 1252811. https://doi.org/10.3389/fimmu.2023.1252811
Penack, Olaf; Peczynski, Christophe; Koenecke, Christian; Polge, Emmanuelle; Sanderson, Robin; Yakoub-Agha, Ibrahim; Fegueux, Nathalie; Daskalakis, Michael; Collin, Matthew; Dreger, Peter; Kröger, Nicolaus; Schanz, Urs; Bloor, Adrian; Ganser, Arnold; Besley, Caroline; Wulf, Gerald G.; Novak, Urban; Moiseev, Ivan; Schoemans, Hélène; Basak, Grzegorz W.; Chabannon, Christian; Sureda, Anna; Glass, Bertram; Perić, Zinaida More authors...

Cite this document

Penack, O., Peczynski, C., Koenecke, C., Polge, E., Sanderson, R., Yakoub Agha, I. ... Perić, Z. (2023). Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. Frontiers in Immunology, 14.. doi: 10.3389/fimmu.2023.1252811

Penack, Olaf, et al. "Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party." Frontiers in Immunology, vol. 14, 2023. https://doi.org/10.3389/fimmu.2023.1252811

Penack, Olaf, Christophe Peczynski, Christian Koenecke, Emmanuelle Polge, Robin Sanderson, Ibrahim Yakoub Agha, Nathalie Fegueux, et al. "Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party." Frontiers in Immunology 14 (2023). https://doi.org/10.3389/fimmu.2023.1252811

Penack, O., et al. (2023) 'Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party', Frontiers in Immunology, 14. doi: 10.3389/fimmu.2023.1252811

Penack O, Peczynski C, Koenecke C, Polge E, Sanderson R, Yakoub Agha I, and sur.. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. Frontiers in Immunology [Internet]. 2023 September 27 [cited 2024 July 11];14. doi: 10.3389/fimmu.2023.1252811

O. Penack, et al., "Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party", Frontiers in Immunology, vol. 14, September 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:165258. [Accessed: 11 July 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
AuthorOlaf Penack
AuthorChristophe Peczynski
AuthorChristian Koenecke
AuthorEmmanuelle Polge
AuthorRobin Sanderson
AuthorIbrahim Yakoub-Agha
AuthorNathalie Fegueux
AuthorMichael Daskalakis
AuthorMatthew Collin
AuthorPeter Dreger
AuthorNicolaus Kröger
AuthorUrs Schanz
AuthorAdrian Bloor
AuthorArnold Ganser
AuthorCaroline Besley
AuthorGerald G. Wulf
AuthorUrban Novak
AuthorIvan Moiseev
AuthorHélène Schoemans
AuthorGrzegorz W. Basak
AuthorChristian Chabannon
AuthorAnna Sureda
AuthorBertram Glass
AuthorZinaida Perić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleFrontiers in Immunology
Numberingvol. 14, 1252811
e-ISSN1664-3224
DOIhttps://doi.org/10.3389/fimmu.2023.1252811
URN:NBNurn:nbn:hr:105:165258
Publication2023-09-27
Document URLhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1252811/full
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-05-17 08:38:20